Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia

Intern Med. 2019 Jan 15;58(2):251-257. doi: 10.2169/internalmedicine.0952-18. Epub 2018 Sep 12.

Abstract

A 40-year-old Japanese man presented with child-onset hypertriglyceridemia recently complicated by diabetes mellitus. The patient's diabetes mellitus was maintained, but he had persistent insulin resistance. The patient also had persistent severe hypertriglyceridemia (1,224-4,104 mg/dL), despite the administration of bezafibrate and ezetimibe. Type V dyslipidemia was revealed by agarose gel electrophoresis and the refrigerator test, and a significantly reduced post-heparin lipoprotein lipase mass of 26 ng/mL was confirmed. Genetic testing confirmed two heterozygous LPL variants, p.Tyr88X and p.Gly215Glu in trans; thus, the patient was diagnosed with lipoprotein lipase deficiency. Lipoprotein lipase deficiency typically arises in type I dyslipidemia, but is latent in type V dyslipidemia.

Keywords: chylomicronemia; lipoprotein lipase; triglycerides.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Age of Onset
  • Bezafibrate / therapeutic use
  • Diabetes Complications* / metabolism
  • Ezetimibe / therapeutic use
  • Genetic Variation
  • Heterozygote
  • Humans
  • Hyperlipoproteinemia Type I / complications*
  • Hyperlipoproteinemia Type I / genetics*
  • Hypertriglyceridemia / complications*
  • Hypertriglyceridemia / drug therapy
  • Hypolipidemic Agents / therapeutic use
  • Insulin Resistance
  • Lipoprotein Lipase / genetics
  • Male

Substances

  • Hypolipidemic Agents
  • Lipoprotein Lipase
  • Ezetimibe
  • Bezafibrate